QUVIVIQ™ (daridorexant) is a dual orexin receptor antagonist, discovered by Idorsia Pharmaceuticals Ltd, that blocks the binding and activity of the wake-promoting neuropeptides known as orexins.
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ (daridorexant) 25 and 50 mg was recently approved and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback